Skip to main content
94 search results for:

Biosimilars 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 05-04-2022 | Biosimilars | Adis Journal Club | Article
    BioDrugs

    Embracing Change: An International Survey Study on the Beliefs and Attitudes of Pediatric Rheumatologists Towards Biosimilars

    Objectives We aimed to reveal the perceptions and attitudes of pediatric rheumatologists towards biosimilars and the obstacles to biosimilar therapy.

  2. 15-10-2021 | Adalimumab biosimilar | News | Article
    approvalsWatch

    EMA recommends approval of two adalimumab biosimilars

    medwireNews : The EMA’s Committee for Medicinal Products for Human Use has recommended approval of two adalimumab biosimilars for the treatment of various rheumatic diseases.

  3. 22-03-2018 | Biosimilars | Editorial | Article

    Biosimilars: The price is not right

    Marc Cohen analyzes the various economic factors influencing the price of biosimilars over recent years in rheumatology, focusing on the United States healthcare system.

  4. 14-05-2021 | Adalimumab biosimilar | News | Article
    News in brief

    Real-world effectiveness may vary with adalimumab biosimilars

    The adalimumab biosimilars GP2107 and SB5 may differ in their rates of discontinuation and remission in routine clinical practice, researchers report.

  5. play
    23-11-2022 | ACR 2022 | Conference coverage | Video

    SURPASS: Secukinumab vs adalimumab biosimilar in axSpA

    Xenofon Baraliakos takes us through SURPASS, a phase 3b head-to-head trial that demonstrated equivalence of secukinumab versus adalimumab biosimilar in patients with radiographic axial spondyloarthritis.

  6. 17-11-2022 | ACR 2022 | Conference coverage | Article

    Secukinumab comparable to adalimumab biosimilar in axSpA

    Researchers have found that secukinumab performs equally well to adalimumab biosimilar for the treatment of radiographic axial spondyloarthritis in a head-to-head trial.

  7. 03-06-2022 | Biosimilars | Adis Journal Club | Article
    Rheumatology and Therapy

    The Non-medical Switch from Reference Adalimumab to Biosimilar Adalimumab is Highly Successful in a Large Cohort of Patients with Stable Inflammatory Rheumatic Joint Diseases: A Real-Life Observational Study

    Bisoendial Abstract Introduction The adalimumab biosimilar (ADAbio) Amgevita® has a similar efficacy and safety profile as the adalimumab reference (ADA) Humira®.

  8. 22-02-2019 | Adalimumab biosimilar | News | Article
    approvalsWatch

    EMA gives nod to two adalimumab biosimilars

    The Committee for Medicinal Products for Human Use has recommended two new adalimumab biosimilars for approval in Europe.

  9. 27-10-2021 | Medications | Adis Journal Club | Article
    Drugs

    Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?

    This review aims to consolidate relevant emerging real-world data and other key information about biosimilar-to-biosimilar cross-switching for prescribing clinicians.

  10. 13-12-2017 | Biosimilars | Feature | Article

    Biosimilars: The story so far

    medwireNews  provides an overview of the evidence supporting the equivalence of biosimilar drugs and their reference products, and answers some questions about the use of biosimilars in rheumatology.

  11. 01-03-2018 | Biosimilars | News | Article
    News in brief

    ACR ‘poised to reconsider’ position on biosimilars

    The American College of Rheumatology has issued a white paper recommending the use of biosimilar agents, when appropriate, for the treatment of rheumatologic diseases.

  12. 13-11-2017 | Biosimilars | Conference report | Article

    ‘The Great Debate’: Should rheumatologists prescribe biosimilars?

    In the “Great Debate” session at the 2017 ACR/ARHP Annual Meeting in San Diego, California, USA, two experts discussed whether patients with rheumatic diseases who are treated with biologic DMARDs should switch to biosimilar agents, focusing on efficacy, safety, and cost.

  13. 16-06-2017 | Rheumatoid arthritis | Conference report | Article
    EULAR 2017

    Adalimumab biosimilars on the horizon

    A number of sessions at EULAR this year have focused on the efficacy and equivalence of biosimilars for the treatment of rheumatoid arthritis; positive findings for two related to the anti-tumor necrosis factor inhibitor adalimumab are reported here.

  14. 18-02-2022 | Osteoporosis | News | Article
    approvalsWatch

    EMA recommends approval of teriparatide biosimilar for osteoporosis

    medwireNews : The EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of a teriparatide biosimilar for the treatment of osteoporosis.

  15. 08-09-2017 | Biosimilars | News | Article

    International recommendations for the use of biosimilars issued

    An international taskforce has developed consensus-based recommendations for the evaluation and use of biosimilars to treat rheumatic diseases.

  16. 18-08-2017 | Biosimilars | Article

    Biosimilars in rheumatology: current perspectives and lessons learnt

    This review updates previous discussions of biosimilars and aspects of biosimilar development, with a focus on the regulatory environment and the latest data on biosimilar tumor necrosis factor (TNF) inhibitors. Dӧrner T, Kay J. Nat Rev Rheumatol . 2015;11:713–724. doi:10.1038/nrrheum.2015.110.

  17. 06-02-2018 | Rheumatoid arthritis | Review | Article

    Biosimilars in rheumatology: Recommendations for regulation and use in Middle Eastern countries

    The increasing availability of biosimilar medicines in Middle Eastern regions may provide an opportunity to increase the number of rheumatology

  18. 22-01-2018 | Image

    Figure 4 : Study design to compare the efficacy of reference drugs and biosimilars.

  19. 07-09-2016 | Biosimilars | Article

    Immunogenicity of biosimilars

    This review provides a summary of current information on factors influencing the immunogenicity, and the evaluation of immunogenicity, of biosimilars, with a review of evidence from infliximab biosimilars. Mirkov S, Hill R. Drugs Ther Perspect . 2016;32:532–538. doi:10.1007/s40267-016-0341-2.

  20. 06-08-2018 | TNF inhibitors | Review | Article

    Non-medical switching from originator tumor necrosis factor inhibitors to their biosimilars: Systematic review of randomized controlled trials and real-world studies

    Numan S, Faccin F. Adv Ther 2018; 9: 1295–1332. doi: 10.1007/s12325-018-0742-9

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.